The application of liposomal azelaic acid, 4-n butyl resorcinol and retinol serum enhanced by microneedling for treatment of malar pattern melasma: A case series


https://doi.org/10.4081/dr.2019.8075
0
0
0
0
Smart Citations
0
0
0
0
Citing PublicationsSupportingMentioningContrasting
View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

Plum Print visual indicator of research metrics
Citations
  • Citation Indexes: 6
Captures
  • Readers: 18

Authors

  • Arie Kusumawardani
    arie_dr2008@yahoo.com
    Dermatovenereology Department Faculty of Medicine Sebelas Maret University dr. Moewardi General Hospital of Surakarta, Indonesia.
  • Anggana Rafika Paramitasari Dermatovenereology Department Faculty of Medicine Sebelas Maret University dr. Moewardi general hospital of Surakarta, Indonesia.
  • Susanti Rosmala Dewi Dermatovenereology Department Faculty of Medicine Sebelas Maret University dr. Moewardi general hospital of Surakarta, Indonesia.
  • Ance Imelda Betaubun Dermatovenereology Department Faculty of Medicine Sebelas Maret University dr. Moewardi general hospital of Surakarta, Indonesia.

Melasma is a common hypermelanosis disorder that can be frustrating both for patients and physicians because it is very difficult to treat. Azelaic acid, 4-n-butylresorcinol and retinol is some of treatment modalities for melasma, but until now there is no clinical trial studies about combination of these three agents. We reported three mixed type melasma patients whom we treated using liposomal serum containing azelaic acid, 4-n-butylresorcinol and retinol combined with microneedling. We measured the improvement with modified Melasma Severity Index (MASI), Melasma Severity Scale (MSS) and Melas-QoL quesionner. At the start of the trial the average MASI score of all patients was 5.9, MSS was moderate and Melas QoL was 55.3. We re-applied treatment every 14 days for four times. There were improvements in their MASI with the ranged of 41.7%-85%, and Melas-QoL 38.8-83.3%. All of MSS in these three patients was classified into mild in the end of therapy.